Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Selectins01:25

Selectins

3.8K
Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.8K
Proteoglycans01:05

Proteoglycans

4.5K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decoding Galectin-Glycan Recognition with <sup>19</sup>F-Tagged Lectins: from Simple Glycans to the Cellular Glycocalyx.

Journal of the American Chemical Society·2026
Same author

Presentation Is Essential for Glycan-Lectin Recognition at the Molecular and Cellular Levels: The Interaction of Tumor-Associated <i>O</i>‑Glycans with the Macrophage Galactose-Type Lectin.

JACS Au·2026
Same author

Publisher Correction: Polyamine-dependent metabolic shielding regulates alternative splicing.

Nature·2026
Same author

Polyamine-dependent metabolic shielding regulates alternative splicing.

Nature·2026
Same author

Rational design of heparin antagonist: Guanidine-based mimetics unveil key carbohydrate-carbohydrate interactions.

European journal of medicinal chemistry·2026
Same author

Galectin-9 binding to HLA-DR in dendritic cells controls immune synapse formation and T cell proliferation.

Proceedings of the National Academy of Sciences of the United States of America·2025

Related Experiment Video

Updated: Dec 10, 2025

Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions
11:21

Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions

Published on: January 20, 2022

3.9K

Targeting Galectins With Glycomimetics.

Sara Bertuzzi1, Jon I Quintana1, Ana Ardá1

  • 1CIC bioGUNE, Basque Research Technology Alliance, Derio, Spain.

Frontiers in Chemistry
|August 28, 2020
PubMed
Summary
This summary is machine-generated.

Researchers are developing novel glycomimetics to target galectins, proteins involved in diseases like cancer and inflammation. These potential drugs show promise in binding and modulating specific galectins for therapeutic applications.

Keywords:
drug designgalectinsglycansglycomimeticsmolecular recogntion

More Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.0K
Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
13:21

Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples

Published on: May 4, 2012

16.1K

Related Experiment Videos

Last Updated: Dec 10, 2025

Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions
11:21

Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions

Published on: January 20, 2022

3.9K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.0K
Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
13:21

Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples

Published on: May 4, 2012

16.1K

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Glycobiology

Background:

  • Galectins are glycan-binding proteins with critical roles in biological processes.
  • Dysregulated galectin activity is linked to diseases including cancer and inflammation.
  • Galectins are attractive targets for novel therapeutic strategies.

Purpose of the Study:

  • To review recent advancements in designing glycomimetics as potential anti-galectin drugs.
  • To explore strategies for creating specific and effective galectin-targeting therapeutics.

Main Methods:

  • Design of glycomimetic molecules with specific functional groups.
  • Utilizing multivalent presentations of lactose and N-acetyl lactosamine analogs.
  • Investigating S-glycosyl compounds, peptidomimetics, and multivalent glycopolymers.

Main Results:

  • Promising results achieved in binding and modulating various galectins.
  • Successful application of glycomimetics in recognizing and detecting human galectins (hGal-1 and hGal-3).
  • Diverse glycomimetic approaches demonstrate potential for therapeutic intervention.

Conclusions:

  • Glycomimetic design offers a promising avenue for developing drugs against galectin-mediated diseases.
  • Targeted glycomimetic strategies can effectively modulate galectin functions.
  • Further development holds potential for novel treatments for cancer and inflammatory conditions.